The role of complement in experimental bullous pemphigoid - PubMed (original) (raw)

The role of complement in experimental bullous pemphigoid

Z Liu et al. J Clin Invest. 1995 Apr.

Abstract

Bullous pemphigoid (BP) is a blistering skin disease associated with an IgG autoimmune response directed against the ectodomain of the hemidesmosomal protein, BP180. An animal model of BP has recently been developed by our laboratory based on the passive transfer of rabbit antimurine BP180 antibodies into neonatal BALB/c mice. The experimental animals develop a blistering disease that reproduces all of the key immunopathological features of BP. In the present study we have investigated the role of complement in the pathogenesis of subepidermal blistering in the mouse model of BP. We demonstrate the following. (a) Rabbit anti-murine-BP180 IgG was effective in inducing cutaneous blisters in a C5-sufficient mouse strain, but failed to induce disease in the syngeneic C5-deficient strain; (b) neonatal BALB/c mice, pretreated with cobra venom factor to deplete complement, became resistant to the pathogenic effects of the anti-BP180 IgG; (c) F(ab')2 fragments generated from the anti-BP180 IgG exhibited no pathogenic activity in the mouse model; and (d) histologic evaluation of the skin of mice described in points b and c above showed minimal or no neutrophilic cell infiltration in the upper dermis. Thus, anti-BP180 antibodies trigger subepidermal blistering in this BP model via complement activation. This experimental model of BP should greatly facilitate future studies on the pathophysiology of autoantibody-mediated diseases of the dermal-epidermal junction.

PubMed Disclaimer

Similar articles

• A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.
  Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. Liu Z, et al. J Clin Invest. 1993 Nov;92(5):2480-8. doi: 10.1172/JCI116856. J Clin Invest. 1993. PMID: 7693763 Free PMC article.
• Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid.
  Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, Werb Z, Liu Z. Chen R, et al. J Clin Invest. 2001 Oct;108(8):1151-8. doi: 10.1172/JCI11494. J Clin Invest. 2001. PMID: 11602622 Free PMC article.
• IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
  Feldrihan V, Licarete E, Florea F, Cristea V, Popescu O, Sitaru C, Chiriac MT. Feldrihan V, et al. Hum Immunol. 2014 Apr;75(4):354-63. doi: 10.1016/j.humimm.2014.01.005. Epub 2014 Jan 24. Hum Immunol. 2014. PMID: 24468586
• Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.
  Leighty L, Li N, Diaz LA, Liu Z. Leighty L, et al. Arch Dermatol Res. 2007 Nov;299(9):417-22. doi: 10.1007/s00403-007-0790-5. Epub 2007 Sep 19. Arch Dermatol Res. 2007. PMID: 17879094 Free PMC article. Review.
• The pathophysiology of bullous pemphigoid.
  Kasperkiewicz M, Zillikens D. Kasperkiewicz M, et al. Clin Rev Allergy Immunol. 2007 Oct;33(1-2):67-77. doi: 10.1007/s12016-007-0030-y. Clin Rev Allergy Immunol. 2007. PMID: 18094948 Review.

Cited by

• Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
  Chen HC, Wang CW, Toh WH, Lee HE, Chung WH, Chen CB. Chen HC, et al. Clin Rev Allergy Immunol. 2023 Dec;65(3):331-353. doi: 10.1007/s12016-023-08973-1. Epub 2023 Oct 28. Clin Rev Allergy Immunol. 2023. PMID: 37897588 Review.
• Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
  Toh WH, Lee HE, Chen CB. Toh WH, et al. Front Med (Lausanne). 2023 Aug 8;10:1196946. doi: 10.3389/fmed.2023.1196946. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37614956 Free PMC article. Review.
• Anti-NC16A IgA from Patients with Linear IgA Bullous Dermatosis Induce Neutrophil-Dependent Subepidermal Blistering in Mice.
  Jing K, Jordan TJM, Li N, Burette S, Yang B, Marinkovich MP, Diaz LA, Googe P, Thomas NE, Feng S, Liu Z. Jing K, et al. J Invest Dermatol. 2024 Jan;144(1):24-32.e1. doi: 10.1016/j.jid.2023.05.027. Epub 2023 Jul 10. J Invest Dermatol. 2024. PMID: 37437774
• Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
  Chen F, Wang Y, Chen X, Yang N, Li L. Chen F, et al. Ann Med. 2023 Dec;55(1):1156-1170. doi: 10.1080/07853890.2023.2188487. Ann Med. 2023. PMID: 36999962 Free PMC article. Review.
• The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.
  Maglie R, Solimani F, Didona D, Pipitò C, Antiga E, Di Zenzo G. Maglie R, et al. Front Med (Lausanne). 2023 Feb 6;10:1128154. doi: 10.3389/fmed.2023.1128154. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36814775 Free PMC article. Review.

References

1. 1. J Invest Dermatol. 1975 Jul;65(1):162-9 - PubMed
2. 1. Immunology. 1975 Feb;28(2):369-77 - PubMed
3. 1. J Immunol. 1976 Jan;116(1):112-6 - PubMed
4. 1. Clin Immunol Immunopathol. 1976 May;5(3):360-70 - PubMed
5. 1. J Clin Invest. 1976 Jun;57(6):1426-31 - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• R01 AR032081/AR/NIAMS NIH HHS/United States
• R37-AR32081/AR/NIAMS NIH HHS/United States
• R01-AR32599/AR/NIAMS NIH HHS/United States
• R29-AR40410/AR/NIAMS NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal